Aldehyde metabolism is potentially linked to numerous diseases and conditions. The underlying body of independently derived research suggests a wide range of potential target diseases for ALDH modulators (both activators and inhibitors), including:

• Orphan indications
• Cardiovascular diseases such as pulmonary artery disease and ischemic heart damage
• Inhibition of cancer cell growth
• Radiation dermatitis
• Management of neurological disorders such as Parkinson's disease

 

Getting to the Heart of Protoemics

 

Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant

 

Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients

 

Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart

 

ALDH2 Activator Inhibits Increased Myocardial Infarction Injury by Nitroglycerin Tolerance